ABL Bio

ABL Bio

Korea - Seongnam
Biotechnology

Focus: Antibody, Immuno-oncology

ABL Bio is a life sciences company focused on Antibody, Immuno-oncology.

Oncology
Open Jobs
0

Pipeline & Clinical Trials

Clinical Trials (1)
NCT06126666A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1
Clinical Trials (1)
NCT05101109Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT03292783This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
Phase 1
ABL301
Healthy
Phase 1
Clinical Trials (1)
NCT05756920This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants
Phase 1
Clinical Trials (1)
NCT04762641This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
Phase 1
Phase 1/2
Clinical Trials (1)
NCT04492033A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2020
Portfolio: 6 clinical trials